FDA Updates Plavix Label, Leaves Effient With Clear Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.
You may also be interested in...
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
Best of the Blog, IN VIVO, November 2009
A selection of our favorite blog posts from November 2009 about stories not covered elsewhere in this issue of IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards